Reference
Falt A, et al. A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3). Multiple Sclerosis Journal 24 (Suppl.): 706-707, No. 2, Oct 2018. Available from: URL: http://doi.org/10.1177/1352458518798591 [abstract] - Sweden
Rights and permissions
About this article
Cite this article
Alemtuzumab. Reactions Weekly 1776, 27 (2019). https://doi.org/10.1007/s40278-019-70185-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-70185-2